Complement factor I-related compositions and methods
Grant E. Blouse, Burlingame, CA (US); Brajesh Kumar, Fremont, CA (US); Tom Knudsen, Burlingame, CA (US); Jan Kristian Jensen, Randers (DK); Emil Oldenburg, Aarhus (DK); Christine René Schar, Randers (DK); Matthew John Traylor, Boulder, CO (US); Eric Steven Furfine, Lincoln, MA (US); Jeffrey Charles Way, Cambridge, MA (US); Agnieszka Jendroszek, Risskov (DK); Arzu Sandikci, Berkeley, CA (US); Jim McGuire, South San Francisco, CA (US); Shyam Rajan Iyer, Woodside, CA (US); and Natacha Le Moan, South San Francisco, CA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Jun. 14, 2021, as Appl. No. 17/347,442.
Claims priority of provisional application 63/179,160, filed on Apr. 23, 2021.
Claims priority of provisional application 63/124,698, filed on Dec. 11, 2020.
Claims priority of provisional application 63/122,437, filed on Dec. 7, 2020.
Claims priority of provisional application 63/038,874, filed on Jun. 14, 2020.
Prior Publication US 2023/0038638 A1, Feb. 9, 2023
1. A fusion construct comprising a first component and a second component, wherein the first component comprises a wild type complement factor I (CFI), wherein the second component comprises a half-life extender, wherein the second component is fused to the N-terminal end of the first component, and wherein the fusion construct has a cleavage activity for C3b and/or C4b that is substantially equivalent to a plasma-derived CFI.